非司妥单抗（Veoza）是一种专门治疗更年期血管舒缩症状的非激素类药物，已于2024年3月在澳大利亚获得批准，每日口服45毫克1。这款药物通过阻断大脑温度调节系统中的神经激肽B信号发挥作用1，工作原理与激素替代疗法截然不同。临床试验结果显示，三个月的治疗能将中重度症状从每日约10至12次减少到4至5次，而安慰剂组的减少幅度为每日6至7次1。
Veoza在澳大利亚不被纳入药物福利计划，患者需自费购买，月均成本约75至80澳元1。常见副作用包括头痛、恶心、腹痛和失眠，此外还有罕见的肝脏损伤病例报告1。因此，澳大利亚和国际监管机构均建议患者在治疗前进行肝功能检测，并在治疗初期九个月内定期监测1。需要注意的是，Veoza仅针对血管舒缩症状（如潮热和夜间盗汗）有效，对其他更年期症状无效1。根据调查，欧洲、英国、美国和日本的患者中约十分之一因各种原因无法使用激素替代疗法1，Veoza的推出为这部分患者提供了替代方案。
Veoza (fezolinetant) has received regulatory approval in Australia as a non-hormonal medication designed specifically to treat vasomotor symptoms—hot flushes and night sweats—associated with menopause 1. The drug became available in March 2024 at a dose of 45 milligrams once daily 1.
Unlike hormone replacement therapy, which works by supplementing estrogen and progestin levels, Veoza operates through a different mechanism by blocking neurokinin B signaling in the brain's temperature regulation system 1. Clinical trials demonstrated that three months of treatment reduced moderate to severe symptoms from approximately 10 to 12 episodes per day to 4 to 5 episodes daily, compared to 6 to 7 episodes in the placebo group 1. However, the medication does not eliminate symptoms entirely and is limited to treating vasomotor symptoms rather than other menopause-related conditions 1.
The medication carries common side effects including headache, nausea, abdominal pain, and insomnia, with rare cases of liver injury reported 1. Australian and international regulatory authorities recommend liver function testing before treatment begins, followed by regular monitoring during the initial nine months of therapy 1. Despite approval, Veoza is not covered under Australia's Pharmaceutical Benefits Scheme, requiring patients to pay approximately 75 to 80 Australian dollars monthly 1. An alternative non-hormonal option, Lynkuet (elinzanetant), targeting NK1 and NK3 receptors with improved liver safety, received approval in September 2025 1. Approximately 40 percent of women experience vasomotor symptoms before menopause, with surveys across Europe, the United Kingdom, the United States, and Japan indicating that one in ten patients cannot tolerate hormone replacement therapy 1.
评论
还没有评论，欢迎留下第一条。